Summary

  • Cerenome’s “up to US$20 million” facility is a maximum purchase-price commitment, not one funded receipt. The company says the initial tranche was funded at closing; the filed schedule assigns US$3 million of cash to US$3.191489 million of initial note principal.
  • A 6% original-issue discount makes the full US$20 million purchase price correspond to US$21.276596 million of principal. The remaining US$2 million second purchase and up to US$15 million of additional purchases sit behind different registration, approval, market and balance-of-note conditions.
  • The 2.5% CNSide gross-revenue royalty is consideration for the financing and expires only after the notes and related amounts are fully settled. The filed royalty agreement does not say those payments reduce principal, so it must be read alongside—not instead of—the note’s cash amortization.

“Up to” is often the hardest-working phrase in a financing announcement. It lets a company present maximum capacity as a single pool even when the contract divides that pool by date, actor and condition. Cerenome’s 10 September announcement calls its arrangement with 3i, LP an up-to-US$20 million senior secured facility with royalty-based repayments. It also says initial funding was received at closing and that later tranches depend on milestones.

The Form 8-K and exhibits describe a more exact machine. There are three purchase-price layers, a larger principal ledger created by original-issue discount, quarterly amortization, conversion rights, first-priority collateral and a separate royalty on the revenue of wholly owned CNSide Diagnostics. Each changes a different part of the company’s cash and control position.

The market question is therefore not whether US$20 million sounds sufficient. It is which receipts become available, what has to be true before each one arrives and how much cash or equity value can leave after it does.

US$20 million of purchase price becomes US$21.276596 million of principal

The securities purchase agreement says the investor pays US$940 for every US$1,000 of original principal. That 6% original-issue discount produces three exact pairs:

  • US$3 million of initial purchase price for US$3.191489 million of initial principal;
  • US$2 million of second purchase price for US$2.127660 million of second principal; and
  • up to US$15 million of additional purchase price for up to US$15.957447 million of additional principal.

At maximum scale, US$20 million of cash purchase price therefore supports US$21.276596 million of face amount. The US$1.276596 million difference is not an additional receipt. It is principal created by the financing terms before interest, amortization premiums, make-whole amounts, fees or the revenue royalty.

The initial receipt is also narrower than the headline. The press release says funding was received at closing. The 8-K describes US$3 million of expected gross proceeds before legal fees and transaction expenses. Neither document gives the exact net cash deposited after deductions. US$3 million is 15% of the maximum purchase-price headline, not proof that the other 85% is already liquid.

That distinction matters against Cerenome’s latest financial baseline. Its second-quarter release reported US$2.366 million of cash and US$6.221 million of investments at 30 June. Six-month operating cash use was US$13.370 million and the net loss was US$15.952 million. Cash plus investments of US$8.587 million was roughly 64% of that historical half-year cash use, although working-capital movements and future spending make that an illustration, not a runway forecast.

Management now forecasts runway well into 2028 after counting the 3i facility, other facilities, current cash and forecast CNSide sales and cash flow. The verbs matter. A forecast that aggregates conditional financing and future operating receipts cannot be reconciled to funded cash until investors can see the draw schedule, the sales receipts and the payments leaving under the same contracts.

The second and additional tranches do not share one gate

The next US$2 million is linked to an effective resale registration statement for the conversion shares underlying the initial and second notes, plus the other closing conditions. It is not merely the passage of time. Registration effectiveness opens one contractual door; it does not by itself establish that every other condition has been satisfied or waived.

The additional US$15 million of maximum purchase price is more complicated because either side can initiate a closing under different rules. The investor can elect additional purchases, generally in principal amounts of at least US$1 million. Cerenome can require additional purchases only when a longer eligibility test is met. Among other things, no more than US$2 million of notes may remain outstanding, at least ten trading days must have passed since another closing, stockholder approval must have been obtained, and there can be no authorised-share, price or volume failure.

For company-mandated closings, each individual additional note is capped at US$5.319149 million of principal, corresponding to US$5 million of purchase price. The relevant resale registration statement must also be effective before the investor is required to pay. Both sides’ additional-closing rights end 18 months after the initial closing.

That architecture makes “available upon achieving certain milestones” too broad for valuation. Some gates concern SEC registration. Others concern shareholder authority, trading price, market liquidity, outstanding note balance and continued compliance with closing representations. The investor also owns an optional draw right. Cerenome does not have unilateral command over the full undrawn amount from day one.

Eight per cent is only the label on the interest line

The form of note bears 8% annual interest and normally matures one year after issuance. Reading only those two terms misses the payment geometry.

Interest is guaranteed through maturity even if principal is converted or redeemed earlier. A make-whole amount captures the additional interest that would otherwise have accrued. The note also says interest is calculated on the entire outstanding original principal without giving effect to prior amortization or redemption, except where that would duplicate the make-whole calculation.

Cash amortization begins three months after a closing and then recurs quarterly. Each scheduled amount contains one quarter of the initial principal, adjusted for specified earlier reductions, plus accrued interest and the make-whole amount. Cerenome must pay 105% of that combined amortization amount. The 6% discount, the 8% stated rate, the guaranteed interest and the 105% redemption factor are therefore separate economic layers, not alternative descriptions of one charge.

Failure to pay a scheduled amortization in cash gives the holder a conversion route at 93% of the lowest VWAP during the preceding ten trading days. A broader event of default can raise interest to as much as 18%, subject to the legal maximum, and open alternate conversion formulas using 85% of specified VWAP tests, with the contractual floor and other limits. A change of control can permit cash redemption with a 120% premium.

None of those clauses proves that conversion or default will occur. They explain why the financing changes the distribution of downside. If cash performance weakens, the creditor’s rights can move from scheduled payment toward discounted equity issuance or premium redemption precisely when the company has fewer easy choices.

The royalty is attached to CNSide’s top line, not described as principal amortization

The financing reaches below the parent company. Under the royalty agreement, CNSide is to pay the investor quarterly royalties equal to 2.5% of gross revenue actually received from third parties for covered business goods and services. Permitted exclusions are narrow: actual customer refunds and similar adjustments, specified remitted taxes and unmarked-up reimbursement of identified third-party costs.

Each quarter’s payment is capped at 2.5% of the unpaid note balance measured on the first day of that quarter. The cap falls with the outstanding obligation, but it is not a published lifetime cap on royalty dollars. The term continues until principal, interest, fees, expenses and all other note amounts are indefeasibly paid in cash or shares and the notes are terminated or cancelled.

Most importantly, the royalty document calls this stream an inducement and part of the consideration for the investor’s participation. It does not say a royalty payment reduces note principal, scheduled amortization or interest. The public phrase “royalty-based repayments” should therefore not collapse the two ledgers. On the filed terms, CNSide can owe its revenue share while Cerenome separately owes note service.

That distinction will become economically visible only when CNSide begins reporting commercial receipts. Cerenome said the business performed 232 cerebrospinal-fluid tests in the first half of 2026 and had reached payer coverage milestones. Yet its condensed statement of operations reported grant revenue, not a separate diagnostic-sales line. Test count, covered lives, orders, billed claims, recognised revenue and cash collected are not interchangeable measures.

A 2.5% royalty on cash actually received will follow the last of those measures. Investors need payer mix, reimbursement timing, denials, collection rates and the covered-revenue report before they can size it. Rapid CNSide growth helps the operating thesis while also increasing the royalty paid to the financier; that is an aligned claim on success, not free capital.

Collateral turns the diagnostics subsidiary into part of the financing perimeter

The notes are not secured only by a parent-company promise. The security agreement provides a first-priority interest in substantially all present and future assets of Cerenome and CNSide, subject to stated exclusions. The package includes accounts, deposit accounts, equipment, intellectual property, proceeds and a pledge of the equity interests in CNSide. Deposit-account control arrangements are required within 30 days after the initial closing.

The note covenants also constrain dividends, redemptions, some other debt payments, asset sales, changes in business and certain new securities. These protections do not put the investor in the laboratory or make it responsible for commercial execution. They do give it a contractually senior position around the assets and cash pathways meant to generate repayment.

This is the second reason the initial US$3 million cannot be read in isolation. Cerenome receives near-term liquidity, while the creditor receives claims that extend across the parent, the diagnostics subsidiary, future revenue, collateral and potential equity. The bargain may still be rational for a company financing commercial scale-up. Its cost, however, cannot be expressed by the coupon alone.

Sources